請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44459
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華(Jih-Hwa Guh) | |
dc.contributor.author | Yu-wei Sun | en |
dc.contributor.author | 孫譽維 | zh_TW |
dc.date.accessioned | 2021-06-15T02:58:53Z | - |
dc.date.available | 2014-09-15 | |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-07-31 | |
dc.identifier.citation | 1. A. L. Potosky, E. J. Feuer, and D. L. Levin. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiologic Reviews. 23:181-186 (2001).
2. B. J. Feldman and D. Feldman. The development of androgen-independent prostate cancer. Nature Reviews Cancer. 1:34-45 (2001). 3. B. N. Breyer, J. M. Whitson, C. E. Freise, and M. V. Meng. Prostate Cancer Screening and Treatment in the Transplant Population: Current Status and Recommendations. Journal of Urology. 181:2018-2025 (2009). 4. T. J. Daskivich and W. K. Oh. Recent progress in hormonal therapy for advanced prostate cancer. Current Opinion in Urology. 16:173-178 (2006). 5. M. E. Taplin, G. J. Bubley, T. D. Shuster, M. E. Frantz, A. E. Spooner, G. K. Ogata, H. N. Keer, and S. P. Balk. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine. 332:1393-1398 (1995). 6. L. Le Marchand. Cancer preventive effects of flavonoids - a review. Biomedicine & Pharmacotherapy. 56:296-301 (2002). 7. A. Tyagi, N. Bhatia, M. S. Condon, M. C. Bosland, C. Agarwal, and R. Agarwal. Antiproliferative and apoptotic effects of Silibinin in rat prostate cancer cells. Prostate. 53:211-217 (2002). 8. R. J. Nijveldt, E. van Nood, D. E. C. van Hoorn, P. G. Boelens, K. van Norren, and P. A. M. van Leeuwen. Flavonoids: a review of probable mechanisms of action and potential applications. American Journal of Clinical Nutrition. 74:418-425 (2001). 9. J. P. Clark, K. W. Munson, K. Lamparska-Kupsik, J. W. Gu, Z. D. Feng, K. G. Chan, J. S. Yoshida, M. H. Kawachi, L. E. Crocitto, T. G. Wilson, and S. S. Smith. Serum PSA, DRE, DNA methylation, PCA3, and TMPRSS2 : ERG in expressed prostatic secretion as non-invasive predictors of biopsy outcome. Journal of Urology. 179:706-706 (2008). 10. I. M. Thompson, C. Chi, D. P. Ankerst, P. J. Goodman, C. M. Tangen, S. M. Lippman, M. S. Lucia, H. L. Parnes, and C. A. Coltman. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute. 98:1128-1133 (2006). 11. S. E. Nielsen, R. Freese, P. Kleemola, and M. Mutanen. Flavonoids in human urine as biomarkers for intake of fruits and vegetables. Cancer Epidemiology Biomarkers & Prevention. 11:459-466 (2002). 12. N. Shaida, C. Jones, N. Ravindranath, and P. R. Malone. The Chances of Subsequent Cancer Detection in Patients with a PSA > 20 ng/ml and an Initial Negative Biopsy. The scientific world journal. 9:343-348 (2009). 13. J. H. Pinthus, J. P. Lu, L. A. Bidaisee, H. Lin, I. Bryskine, R. S. Gupta, and G. Singh. Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer. Prostate. 67:1330-1338 (2007). 14. Y. S. Zhu and J. L. Imperato-McGinley. 5 alpha-Reductase Isozymes and Androgen Actions in the Prostate. Steroid Enzymes and Cancer. 1155:43-56 (2009). 15. I. Urquiaga and F. Leighton. Plant polyphenol antioxidants and oxidative stress. Biological Research. 33:55-64 (2000). 16. P. G. Pietta. Flavonoids as antioxidants. Journal of Natural Products. 63:1035-1042 (2000). 17. J. D. O'Reilly, T. A. B. Sanders, and H. Wiseman. Flavonoids protect against oxidative damage to LDL in vitro: Use in selection of a flavonoid rich diet and relevance to LDL oxidation resistance ex vivo? Free Radical Research. 33:419-426 (2000). 18. N. C. Cook and S. Samman. Flavonoids - Chemistry, metabolism, cardioprotective effects, and dietary sources. Journal of Nutritional Biochemistry. 7:66-76 (1996). 19. S. G. Khan, S. K. Katiyar, R. Agarwal, and H. Mukhtar. Enhancement of antioxidant and phase-II enzymes to SKH-1 hairless mice-possible role in cancer chemoprevention. Cancer Research. 52:4050-4052 (1992). 20. N. Joza, S. A. Susin, E. Daugas, W. L. Stanford, S. K. Cho, C. Y. J. Li, T. Sasaki, A. J. Elia, H. Y. M. Cheng, L. Ravagnan, K. F. Ferri, N. Zamzami, A. Wakeham, R. Hakem, H. Yoshida, Y.-Y. Kong, T. W. Mak, J. C. Zuniga-Pflucker, G. Kroemer, and J. M. Penninger. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 410:549-554 (2001). 21. G. Kroemer, B. Dallaporta, and M. Resche-Rigon. The mitochondrial death/life regulator in apoptosis and necrosis. Annual Review of Physiology. 60:619-642 (1998). 22. F. Mollinedo and C. Gajate. Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy. Drug Resistance Updates. 9:51-73 (2006). 23. A. Ashkenazi. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Review Cancer. 2:420-430 (2002). 24. G. Nunez, M. A. Benedict, Y. M. Hu, and N. Inohara. Caspases: the proteases of the apoptotic pathway. Oncogene. 17:3237-3245 (1998). 25. D. Lechardeur, L. Drzymala, M. Sharma, D. Zylka, R. Kinach, J. Pacia, C. Hicks, N. Usmani, J. M. Rommens, and G. L. Lukacs. Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD). Journal of Cell Biology. 150:321-334 (2000). 26. R. U. Jaenicke, M. L. Sprengart, M. R. Wati, and A. G. Porter. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. Journal of Biological Chemistry. 273:9357-9360 (1998). 27. H. R. Stennicke, J. M. Jurgensmeier, H. Shin, Q. Deveraux, B. B. Wolf, X. H. Yang, Q. Zhou, H. M. Ellerby, L. M. Ellerby, D. Bredesen, D. R. Green, J. C. Reed, C. J. Froelich, and G. S. Salvesen. Pro-caspase-3 is a major physiologic target of caspase-8. Journal of Biological Chemistry. 273:27084-27090 (1998). 28. G. Kroemer and J. C. Reed. Mitochondrial control of cell death. Nature Medicine. 6:513-519 (2000). 29. H. Sakahira, M. Enari, and S. Nagata. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 391:96-99 (1998). 30. V. Viswanath, Y. Q. Wu, R. Boonplueang, S. Chen, F. F. Stevenson, F. Yantiri, L. C. Yang, M. F. Beal, and J. K. Andersen. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. Journal of Neuroscience. 21:9519-9528 (2001). 31. W. C. Earnshaw, L. M. Martins, and S. H. Kaufmann. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annual Review of Biochemistry. 68:383-424 (1999). 32. G. S. Salvesen and C. S. Duckett. IAP proteins: blocking the road to death's door. Nature Review Molecular Cell Biology. 3:401-410 (2002). 33. Q. L. Deveraux and T. C. Reed. IAP family proteins - suppressors of apoptosis. Genes & Development. 13:239-252 (1999). 34. S. J. Riedl and Y. Shi. Molecular mechanisms of caspase regulation during apoptosis. Nature Review Moleccular Cell Biology. 5:897-907 (2004). 35. Y. Tsujimoto and S. Shimizu. Bcl-2 family: Life-or-death switch. FEBS Letters. 466:6-10 (2000). 36. X. J. Liu, L. Q. Zhang, X. L. Liu, and F. C. He. Role for the Bcl-2 family proteins and BH3 domain in apoptosis. Progress in Biochemistry and Biophysics. 33:221-225 (2006). 37. N. A. Thornberry and Y. Lazebnik. Caspases: Enemies within. Science. 281:1312-1316 (1998). 38. M. H. Harris and C. B. Thompson. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death and Differentiation. 7:1182-1191 (2000). 39. D. G. Breckenridge and D. Xue. Regulation of mitochondrial membrane premeabilization by BCL-2 family proteins and caspases. Current Opinion in Cell Biology. 16:647-652 (2004). 40. D. Cossarizza. Mitochondria and apoptosis: functional studies on membrane potential (Delta Psi). Minerva Biotecnologica. 12:57-61 (2000). 41. K. Kaldi and W. Neupert. Protein translocation into mitochondria. Biofactors. 8:221-224 (1998). 42. P. Costantini, E. Jacotot, D. Decaudin, and G. Kroemer. Mitochondrion as a novel target of anticancer chemotherapy. Journal of the National Cancer Institute. 92:1042-1053 (2000). 43. S. Desagher and J. C. Martinou. Mitochondria as the central control point of apoptosis. Trends in Cell Biology. 10:369-377 (2000). 44. N. Wiedemann, N. Pfanner, and M. T. Ryan. The three modules of ADP/ATP carrier cooperate in receptor recruitment and translocation into mitochondria. Embo Journal. 20:951-960 (2001). 45. M. Crompton. Mitochondrial intermembrane junctional complexes and their role in cell death. Journal of Physiology-London. 529:11-21 (2000). 46. A. Eastman. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. Journal of Cellular Biochemistry. 91:223-231 (2004). 47. D. Karunagaran, J. Joseph, and T. R. S. Kumar. Cell growth regulation. Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. 595:245-268 (2007). 48. K. L. King and J. A. Cidlowski. Cell-cycle and apoptosis-common pathways to life and death. Journal of Cellular Biochemistry. 58:175-180 (1995). 49. L. H. Hartwell and M. B. Kastan. Cell-cycle control and cancer. Science. 266:1821-1828 (1994). 50. H. Mueller, J. Lukas, A. Schneider, P. Warthoe, J. Bartek, M. Eilers, and M. Strauss. Cyclin D1 expression is regulated by the retinoblastoma protein. Proceedings of the National Academy of Sciences of the United States of America. 91:2945-2949 (1994). 51. L. A. Bell and K. M. Ryan. Life and death decisions by E2F-1. Cell Death and Differentiation. 11:137-142 (2004). 52. L. H. Hartwell and T. A. Weinert. Checkpoints-controls that ensure the order of cell-cycle events. Science. 246:629-634 (1989). 53. J. Blenis, X. Ma, M. Holz, C. Richardson, and R. Anjum. mTOR-S6K1 signaling and cell growth control. Ejc Supplements. 5:44-44 (2007). 54. M. Rosner, M. Hanneder, N. Siegel, A. Valli, C. Fuchs, and M. Hengstschlager. The mTOR pathway and its role in human genetic diseases. Mutation Research-Reviews in Mutation Research. 659:284-292 (2008). 55. K. Hara, K. Yonezawa, Q. P. Weng, M. T. Kozlowski, C. Belham, and J. Avruch. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. Journal of Biological Chemistry. 273:14484-14494 (1998). 56. L. Asnaghi, P. Bruno, M. Priulla, and A. Nicolin. mTOR: a protein kinase switching between life and death. Pharmacological Research. 50:545-549 (2004). 57. H. Ban, K. Shigemitsu, T. Yamatsuji, M. Haisa, T. Nakajo, M. Takaoka, T. Nobuhisa, M. Gunduz, N. Tanaka, and Y. Naomoto. Arginine and leucine regulate p70 S6 kinase and 4E-BP1 in intestinal epithelial cells. International Journal of Molecular Medicine. 13:537-543 (2004). 58. J. Averous and C. G. Proud. When translation meets transformation: the mTOR story. Oncogene. 25:6423-6435 (2006). 59. E. A. Dunlop and A. R. Tee. Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cellular Signalling. 21:827-835 (2009). 60. N. Sonenberg. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire. 86:178-183 (2008). 61. J. F. Gera, I. K. Mellinghoff, Y. J. Shi, M. B. Rettig, C. Tran, J. H. Hsu, C. L. Sawyers, and A. K. Lichtenstein. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. Journal of Biological Chemistry. 279:2737-2746 (2004). 62. M. Marderosian, A. P. Sharma, A. P. Funk, R. Vartanian, J. Masri, O. D. Jo, and J. F. Gera. Tristetraprolin regulates Cyclin D1 and c-myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 25:6277-6290 (2006). 63. F. Meric-Bernstam and A. M. Gonzalez-Angulo. Targeting the mTOR Signaling Network for Cancer Therapy. Journal of Clinical Oncology. 27:2278-2287 (2009). 64. R. J. Shaw. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiologica. 196:65-80 (2009). 65. S. M. Coustard, A. Collin, E. Audouin, S. Crochet, J. Dupont, and S. Tesseraud. AMPK regulates the S6K1 pathway and protein synthesis in avian QM7 myoblasts. Energy and Protein Metabolism and Nutrition:181-182 (2007). 66. A. S. Green, J. Tamburini, L. Willems, N. Chapuis, S. Park, V. Bardet, M. Foretz, B. Viollet, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, and D. Bouscary. mTORC1 Activity Is Independent of PI3K/Akt but Controlled by AMPK in Acute Myeloid Leukemia. Blood. 112:345-346 (2008). 67. S. M. Hadad, S. Fleming, and A. M. Thompson. Targeting AMPK: A new therapeutic opportunity in breast cancer. Critical Reviews in Oncology Hematology. 67:1-7 (2008). 68. D. M. Thomson, C. A. Fick, and S. E. Gordon. AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions. Journal of Applied Physiology. 104:625-632 (2008). 69. K. Yu, L. Toral-Barza, C. Discafani, W. G. Zhang, J. Skotnicki, P. Frost, and J. J. Gibbons. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Related Cancer. 8:249-258 (2001). 70. E. Tokunaga, E. Oki, A. Egashira, N. Sadanaga, M. Morita, Y. Kakeji, and Y. Maehara. Deregulation of the Akt pathway in human cancer. Current Cancer Drug Targets. 8:27-36 (2008). 71. O. Dangles and C. Dufour. Flavonoid-Protein Binding Processes and their Potential Impact on Human Health. Recent Advances in Polyphenol Research, Vol 1. 1:67-87 (2008). 72. F. T. Hatch, F. C. Lightstone, and M. E. Colvin. Quantitative structure-activity relationship of flavonoids for inhibition of heterocyclic amine mutagenicity. Environmental and Molecular Mutagenesis. 35:279-299 (2000). 73. S. vanAcker, D. J. vandenBerg, M. Tromp, D. H. Griffioen, W. P. VanBennekom, W. J. F. VanderVijgh, and A. Bast. Structural aspects of antioxidant activity of flavonoids. Free Radical Biology and Medicine. 20:331-342 (1996). 74. Y. H. Park and G. C. Y. Chiou. Structure-activity relationship (SAR) between some natural flavonoids and ocular blood flow in the rabbit. Journal of Ocular Pharmacology and Therapeutics. 20:35-42 (2004). 75. D. E. Bredesen. Apoptosis: Overview and signal transduction pathways. Journal of Neurotrauma. 17:801-810 (2000). 76. U. Sartorius, I. Schmitz, and P. H. Krammer. Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem. 2:20-29 (2001). 77. I. Schmitz, S. Kirchhoff, and P. H. Krammer. Regulation of death receptor-mediated apoptosis pathways. International Journal of Biochemistry & Cell Biology. 32:1123-1136 (2000). 78. J. M. Adams and S. Cory. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322-1326 (1998). 79. B. Antonsson. Inhibition of Bax channel-forming activity by Bcl-2. Science. 277:370-372 (1997). 80. E. H. Cheng, B. Levine, L. H. Boise, C. B. Thompson, and J. M. Hardwick. Bax-independent inhibition of apoptosis by Bcl-xL. Nature. 379:554-556 (1996). 81. J. Bae, C. P. Leo, S. Y. Hsu, and A. J. W. Hsueh. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. Journal of Biological Chemistry. 275:25255-25261 (2000). 82. J. Han, L. A. Goldstein, B. R. Gastman, C. J. Froelich, X. M. Yin, and H. Rabinowich. Degradation of Mcl-1 by granzyme B - Implications for Bim-mediated mitochondrial apoptotic events. Journal of Biological Chemistry. 279:22020-22029 (2004). 83. S. Shimizu, T. Ide, T. Yanagida, and Y. Tsujimoto. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. Journal of Biological Chemistry. 275:12321-12325 (2000). 84. S. Shimizu, M. Narita, and Y. Tsujimoto. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483-487 (1999). 85. S. Shimizu, Y. Shinohara, and Y. Tsujimoto. Bax and Bcl-x(L) independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene. 19:4309-4318 (2000). 86. J. M. Jurgensmeier. Bax directly induces release of cytochrome c from isolated mitochondria. Proc. Natl Acad. Sci. USA. 95:4997-5002 (1998). 87. M. Zoratti and I. Szabo. The mitochondrial permeability transition. Biochim. Biophys. Acta. 1241:139-176 (1995). 88. U. Maurer, C. Charvet, A. S. Wagman, E. Dejardin, and D. R. Green. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Molecular Cell. 21:749-760 (2006). 89. D. R. Green and J. C. Reed. Mitochondria and apoptosis. Science. 281:1309-1312 (1998). 90. B. Kadenbach, R. Ramzan, and S. Vogt. Degenerative diseases, oxidative stress and cytochrome c oxidase function. Trends in Molecular Medicine. 15:139-147 (2009). 91. I. Lee, E. Bender, S. Arnold, and B. Kadenbach. New control of mitochondrial membrane potential and ROS formation - A hypothesis. Biological Chemistry. 382:1629-1636 (2001). 92. A. Hahn-Windgassen, V. Nogueira, C. C. Chen, J. E. Skeen, N. Sonenberg, and N. Hay. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. Journal of Biological Chemistry. 280:32081-32089 (2005). 93. J. Averous, B. D. Fonseca, and C. G. Proud. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene. 27:1106-1113 (2008). 94. S. Hashemolhosseini, Y. Nagamine, S. J. Morley, S. Desrivieres, L. Mercep, and S. Ferrari. Rapamycin inhibition of the G(1) to S transition is mediated by effects on cyclin D1 mRNA and protein stability. Journal of Biological Chemistry. 273:14424-14429 (1998). 95. M. J. James and J. Zomerdijk. Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients. Journal of Biological Chemistry. 279:8911-8918 (2004). 96. M. A. Bjornsti and P. J. Houghton. The TOR pathway: A target for cancer therapy. Nature Reviews Cancer. 4:335-348 (2004). 97. T. Schmelzle and M. N. Hall. TOR, a central controller of cell growth. Cell. 103:253-262 (2000). 98. M. Narita, S. Nunez, E. Heard, A. W. Lin, S. A. Hearn, D. L. Spector, G. J. Hannon, and S. W. Lowe. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 113:703-716 (2003). 99. H. Mizuguchi, Z. L. Xu, A. Ishii-Watabe, E. Uchida, and T. Hayakawa. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Molecular Therapy. 1:376-382 (2000). 100. S. Vagner, B. Galy, and S. Pyronnet. Irresistible IRES - Attracting the translation machinery to internal ribosome entry sites. Embo Reports. 2:893-898 (2001). 101. A. Y. Chan, C. L. M. Soltys, M. E. Young, C. G. Proud, and J. R. Dyck. Activation of AMP-activated protein kinase inhibits cardiac myocyte hypertrophy induced by Akt. Circulation. 110:918 (2004). 102. S. Kovacic, C. L. M. Soltys, A. J. Barr, I. Shiojima, K. Walsh, and J. R. B. Dyck. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. Journal of Biological Chemistry. 278:39422-39427 (2003). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/44459 | - |
dc.description.abstract | 前列腺癌為致命且廣泛存在於全世界的癌症之一,容易由前列腺擴散至骨頭和淋巴結。阻斷二氫睪酮素常用於治療前列腺癌,可以阻止癌細胞生長並使其縮小。然而,前列腺癌常於荷爾蒙阻斷治療一至兩年後產生抗性。因此,找尋新穎且有效的治療藥物,來對抗荷爾蒙不依賴型的前列腺癌是有意義的。類黃酮衍生物 WJ-970808-10,發現可有效抑制荷爾蒙不依賴型前列腺癌細胞 PC-3 和DU-145 的生長,其 GI50 分別為 5.86 和 9.21 μM。使用流式細胞儀分析發現, WJ-970808-10 可以引起 PC-3 癌細胞週期 SubG1 期的增加和 G0/G1 期的停滯,其效果和處理時間成正相關。此外還觀測到一些粒線體訊息,包括:粒線體膜電位去極化、Mcl-1、 Bak、Bad、Bim、Bid 的裂解、凋亡物質 cytochrome c 和 AIF 的釋出、ROS 的生成、survivin 的減少和 caspase cascade 的活化,至於死亡受器之相關訊息則無顯著變化。另外,處理藥物短時間可使細胞週期調控者 Cyclin D1、Cdk4、Cyclin E、Cdk2、Cdc25A 和 E2F 表現量減少與 p21 和 p27 表現量增加及 Rb 磷酸化減少。推測 WJ-970808-10 藉由造成細胞週期調控者Cyclin D1、Cdk4、Cyclin E、cdk2 的表現量減少,使細胞週期停滯在 G0/G1 期。使用 RT-PCR 證實 WJ-970808-10 處理 6 小時後,會減少 Cyclin D 和 Cyclin E 的 mRNA 表現,但對 cdk4、cdk2 的 mRNA 表現量則無顯著影響。此外 mTOR 下游 p70S6K (T389/T421/S424)、4E-BP-1 (T37/T46) 和 eIF4E (S209) 的磷酸化於 WJ-970808-10 處理 3小時後明顯受到抑制。以上結果得知,WJ-970808-10 在荷爾蒙不依賴型前列腺癌細胞 PC-3 中會藉由 mTOR 的抑制、造成粒線體損傷與 caspase cascade 的活化,引發細胞週期停滯和後期的細胞凋亡。 | zh_TW |
dc.description.abstract | Prostate cancer is one of the most malignant and prevalent cancer types worldwide and easily spread from prostate to bone and lymph nodes. Blocking dihydrotestosterone (DHT) often causes prostate cancer to stop growing and even shrink. However, cancer cells which initially respond to hormonal therapy usually become chemo-resistant after one- to two-year therapy. Therefore, it is important to discover effective chemotherapeutic agents for treatment of hormone-independent prostate cancer. WJ-970808-10, a flavonoid derivative, suppressed cell growth in hormone-independent prostate cancer cell lines, including PC-3 and DU-145, with GI50 values of 5.86 and 9.21 μM respectively. In flow cytometry analysis, WJ-970808-10 induced an increase of cell population at SubG1 and G0/G1 phase of the cell-cycle in PC-3 cells in a time-dependent manner. The detection of cellular events, including the loss of mitochondria membrane potential, cleavage of Mcl-1, Bak, Bad, Bim and Bid, release of cytochrome c and AIF, production of ROS, down-regulation of survivin and activation of caspase cascade, suggested that mitochondria-related singnals were involved in WJ-970808-10-induced cell apoptosis. However, WJ-970808-10 had little effect on death receptor-related signals. The data also demonstrated that several cell-cycle regulators, including Cyclin D1, Cdk4, Cyclin E, Cdk2, Cdc25A, Rb, E2F, p21 and p27, were affectd by WJ-970808-10. The data suggested that WJ-970808-10 induced down-regulation of Cyclin D1, cdk4, Cyclin E and cdk2, leading to G0/G1 arrest of the cell-cycle. The mRNA level of cell cycle regulators was also examined by RT-PCR and the data showed that the mRNA levels of Cyclin D and Cyclin E, but not cdk4 and cdk2, were down-regulated after a 6-hour treatment of WJ-970808-10. Moreover, downstream factors of mTOR signaling, including the phosphorylation of p70S6K (T389/T421/S424) and 4E-BP-1 (T37/T46), were significantly inhibited after a 3-hour treatment of WJ-970808-10, suggesting the translation-inhibitory activity of this compound. Taken together, WJ-970808-10 induces G1 arrest of the cell-cycle and subsequent apoptosis of human prostate cancer cells through inhibition of mTOR-related pathways, induction of mitochondrial stress and activation of caspases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:58:53Z (GMT). No. of bitstreams: 1 ntu-98-R96423024-1.pdf: 4136878 bytes, checksum: 8cffb26d23b208bc43e041b70cc0c12f (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 圖目錄 ………………………………………………………………………III
中文摘要 ………………………………………………………………………V 英文摘要 ………………………………………………………………………VI 縮寫表 ………………………………………………………………………VIII 一、研究動機 ………………………………………………………………………1 二、文獻回顧 ………………………………………………………………………2 2.1 前列腺癌之背景 …………………………………………….2 2.2 類黃酮之功效 ……………………………………………….3 2.3 細胞凋亡 (apoptosis) 和細胞壞死 (necrosis) ……….4 2.4 細胞週期 ……………………………………………….....9 2.5 mTOR之訊息調控 ……………………………………………10 三、實驗材料 ………………………………………………....14 四、實驗方法 ……………………………………………………15 4.1 細胞培養 ……………………………………………………15 4.2 細胞計數 ……………………………………………………15 4.3 細胞存活率測定 (SRB assay) ……………………………15 4.4 流式細胞儀 (flow cytometry) 測定細胞週期和細胞凋亡 ……………...........................................16 4.5 流式細胞儀 (flow cytometry) 測定測定粒線體膜電位 ……………….........................................16 4.6 流式細胞儀 (flow cytometry) 測定活性氧生成 ………17 4.7 西方墨點法 (Western blotting………………………….17 4.8 細胞轉化 (transformation)、挑選 (screening)、轉染 (transfection) ……………………………………………………………..…….18 4.9 RT-PCR (reverse transcription-polymerase chain reaction) …….......................................19 4.10 分離粒線體 …………………..………………………….21 4.11 [H3]-leucine incorporation assay ………………….21 4.12 資料分析 …………………………..…………………….21 五、實驗結果 ……………………………..…………………..23 六、實驗討論 ………………………………..………………..28 七、結論 ………………………………………………..……..36 八、圖表 ………………………………………………..………37 九、參考文獻 ……………………………………………………65 | |
dc.language.iso | zh-TW | |
dc.title | 類黃酮衍生物對人類雄激素不依賴型前列腺癌細胞的抗癌作用機轉探討 | zh_TW |
dc.title | Investigation of Anticancer Mechanism of Flavonoid Derivative in Human Androgen-Independent Prostate Cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃聰隆(Tsong-Long Hwang),孔繁璐(Fan-Lu Kung),蕭哲志(George Hsiao),楊家榮(Chia-Ron Yang) | |
dc.subject.keyword | 類黃酮,細胞凋亡,細胞週期,mTOR 訊息傳遞,粒線體膜電位, | zh_TW |
dc.subject.keyword | Flavonoid,apoptosis,cell cycle,mTOR pathway,mitochondria membrance potential, | en |
dc.relation.page | 73 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 4.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。